Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making
BJU International · 2025
DOI: 10.1111/bju.16798 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Riccardo Leni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Watchful Waiting, Prostate. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Objectives
To evaluate whether long‐term magnetic resonance imaging (MRI) findings, alone or in combination with prostate‐specific antigen (PSA) density or the result of prior surveillance biopsies, could be used to omit biopsies occurring after patients have been on active surveillance (AS) for ≥5 years. Patients and Methods Analysis of a single‐institution AS cohort of patients with Grade Group (GG) 1 prostate cancer who underwent a scheduled 6‐year MRI and biopsy. Multivariable logistic regression was used to test the association between the Prostate Imaging‐Reporting and Data System (PI‐RADS) score, PSA density, status of prior AS biopsy, and reclassification to GG ≥2. We then analysed how many GG ≥2 cancers would be missed if the 6‐year biopsy was avoided based on significant predictors.
Results
In all, 49 of 221 men (22%) were reclassified to GG ≥2. PSA density and PI‐RADS scores 4–5 were significant predictors; a prior negative AS biopsy was inversely associated with GG ≥2. The risk of missing GG ≥2 if the 6‐year biopsy is omitted in men with an unsuspicious MRI (PI‐RADS 1–2) was 12% (95% confidence interval [CI] 5.3–19%). After testing combinations of MRI findings, PSA density, and the status of the prior biopsy, we found the lowest risk of GG ≥2 in patients with a prior negative biopsy and PSA density of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Division of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.
- Division of Urological Cancers, Department of Translational Medicine, Medical Faculty, Lund University, Lund, Sweden.
ORCID-Profile: Riccardo Leni, Francesco Montorsi, Andrew J Vickers, Behfar Ehdaie
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Leni, R., Tin, A. L., Liso, N., Carlsson, S. V., Akin, O., Montorsi, F., Briganti, A., Eastham, J. A., Vickers, A. J., & Ehdaie, B. (2025). Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making. BJU International. https://doi.org/10.1111/bju.16798
Vancouver
Leni R, Tin AL, Liso N, Carlsson SV, Akin O, Montorsi F, et al. Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making. BJU International. 2025. doi:10.1111/bju.16798
BibTeX
@article{Leni2025,
author = {Leni, Riccardo and Tin, Amy L and Liso, Nicole and Carlsson, Sigrid V and Akin, Oguz and Montorsi, Francesco and Briganti, Alberto and Eastham, James A and Vickers, Andrew J and Ehdaie, Behfar},
title = {Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16798}
}
EUVIMED